EuroBiotech: More Articles of Note

Newspapers

> Destiny Pharma filed for an IPO on London’s AIM. The antimicrobial biotech hired a CEO with IPO experience in April. And has now tapped into that experience to put together an offering to fund its lead candidate up to the start of a pivotal phase 3 program. Statement

> Merck Ventures invested in Macrophage Pharma. The VC offshoot of Merck KGaA added to the £9 million Macrophage raised from investors including Novo Holdings A/S in January. Fueled by the additional cash, Macrophage is now aiming to wrap up a clinical trial using the series A, an advance on its earlier aspiration to get to the end of preclinical development. Release

> Orchard Therapeutics’ gene therapy picked up a promising innovative medicine designation in the United Kingdom. The status is the first step on a pathway that could result in patients in the U.K. gaining early access to the treatment for “bubble boy” disease. Statement

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Ablynx put partnering plans for vobarilizumab on hold. AbbVie turned down the chance to license the phase 3-ready rheumatoid arthritis drug last year, prompting Ablynx to start looking for a new partner. Now, Ablynx has put the search on ice until after it posts data on the drug in systemic lupus erythematosus in the first half of next year. Release    

> Boehringer Ingelheim began a phase 2a NASH trial. Statement

> AC Immune talked up new additions to its preclinical neurodegenerative pipeline. Release

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.